Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cell membrane-anchored/CSV-targeted IL-12-expressing T lymphocytes

A preparation of T lymphocytes engineered to express cell membrane-anchored and cell-surface vimentin (CSV)-targeted interleukin-12 (IL-12), with potential immunostimulatory and antineoplastic activities. Upon administration, the cell membrane-anchored/CSV-targeted IL-12-expressing T lymphocytes are directed to and induce selective toxicity in CSV-expressing tumor cells. The cell membrane-anchored IL-12 cytokine promotes the secretion of interferon-gamma (IFNg), activates natural killer cells (NKs), and induces cytotoxic T-lymphocyte (CTL) responses against tumor cells locally, which may result in immune-mediated tumor cell death and the inhibition of tumor cell proliferation. Vimentin, overexpressed in various tumors, is associated with tumor growth and metastasis. Cell membrane-anchored IL-12 reduces the circulating levels of the inflammatory cytokine and the associated systemic adverse effects.
Synonym:attIL12 armed T cells
attIL12-expressing T-cells
attIL12-T cells
cell membrane-anchored/tumor-targeted IL-12-expressing T cells
Search NCI's Drug Dictionary